New Zealand's Medsafe Approves First Medicine Under the Rule of Two Pathway on 12 November: Paliperidone Injection Cleared in 25 Working Days, About 10 Months Faster

Paliperidone is the first medicine to be approved in New Zealand via the expedited Rule of Two pathway, Associate Health Minister David Seymour announced on 12 November 2026. The pathway, introduced last year, allows medicines to be approved within 30 days if the product has approval from two recognised overseas jurisdictions.
The policy starts with recognising regulators from Australia, the United States, Canada, the United Kingdom, the European Union medicines agency, Singapore and Switzerland. Medsafe approved paliperidone in 25 working days using the Rule of Two, around 10 months faster than expected without it, Mr Seymour said.
Rather than repeating a full assessment, Medsafe verified that the medicine proposed for New Zealand was the same as the product approved overseas and assessed factors relevant to its use in the New Zealand context. The medicine is a paliperidone injection used to treat adults with schizophrenia and schizoaffective disorders, approved as a first-line treatment.
Mr Seymour said the first approval shows the pathway works in practice without compromising safety standards, and that Medsafe has had positive discussions with several more companies interested in using the process.
Source: New Zealand Government
Published by GSM · USA (original Chinese edition)
Photo: Wikimedia Commons, File:Beehive, Wellington, New Zealand (97).JPG — Author: Michal Klajban. Licensing: CC BY-SA 4.0.
Canada Launches AVOID-Methane at COP31 on 13 November to Take Canadian Methane Solutions Global, and Takes the Chair of the Global Methane Initiative2026-11-16
Irish Government Launches Tender on 13 November for a Dublin to Derry Air Service: Contract of Up to Four Years, Starting No Later Than 28 March 20272026-11-16